AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
If you are wondering whether AbbVie is still reasonably priced after a strong multi year run, the key issue is how its ...
A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the ...
StockStory.org on MSN
AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
Over the past six months, AbbVie has been a great trade, beating the S&P 500 by 5.6%. Its stock price has climbed to $233.25, representing a healthy 11.2% increase. This was partly thanks to its solid ...
AbbVie (ABBV) shares continue to drift higher, maintaining their positive momentum into late February. The shares are ...
AbbVie ( (ABBV)) has issued an update. On March 4, 2026, AbbVie completed an underwritten public notes offering totaling $8 billion, spanning a mix of senior floating rate notes and unsecured ...
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate ...
On February 24, 2026, AbbVie entered into an underwriting agreement with a syndicate of major banks to issue a total of $7.5 billion in senior notes across multiple tranches maturing between 2028 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results